(Q41441414)

30 September 2017

title

Clinical improvement in psoriasis with specific targeting of interleukin-23. (English)

1 reference

30 September 2017

Tamara Kopp

1

1 reference

30 September 2017

Elisabeth Riedl

2

1 reference

30 September 2017

Christine Bangert

3

1 reference

30 September 2017

Edward P Bowman

4

1 reference

30 September 2017

Elli Greisenegger

5

1 reference

30 September 2017

Ann Horowitz

6

1 reference

30 September 2017

Harald Kittler

7

1 reference

30 September 2017

Wendy M Blumenschein

8

1 reference

30 September 2017

Terrill K McClanahan

9

1 reference

30 September 2017

Thomas Marbury

10

1 reference

30 September 2017

Claus Zachariae

11

1 reference

30 September 2017

Danlin Xu

12

1 reference

30 September 2017

Xiaoli Shirley Hou

13

1 reference

30 September 2017

Anish Mehta

14

1 reference

30 September 2017

Anthe S Zandvliet

15

1 reference

30 September 2017

Diana Montgomery

16

1 reference

30 September 2017

Frank van Aarle

17

1 reference

30 September 2017

Sauzanne Khalilieh

18

1 reference

30 September 2017

language of work or name

English

0 references

publication date

9 March 2015

1 reference

30 September 2017

1 reference

30 September 2017

volume

521

1 reference

30 September 2017

issue

7551

1 reference

30 September 2017

page(s)

222-226

1 reference

https://scigraph.springernature.com/pub.10.1038/nature14175

30 September 2017

exact match

0 references

cites work

Pathogenesis and therapy of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

21 January 2018

Immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

A balance of interleukin-12 and -23 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Histologic grading system for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Dendritic cells in atopic dermatitis: expression of FcepsilonRI on two distinct inflammation-associated subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14175

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

21 January 2018

1 reference

12 December 2020

Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells

1 reference

12 December 2020

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

1 reference

12 December 2020

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

12 December 2020

1 reference

12 December 2020

The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis

1 reference

12 December 2020

Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NATURE14175

1 reference

Dimensions Publication ID

30 September 2017

1045285060

0 references

1 reference